Report Overview: The Global Allergic Rhinitis Drugs Market achieved a valuation of $1.7 Billion in 2022 and is anticipated to exceed $2.2 Billion by 2030, reflecting a compounded annual growth rate (CAGR) of 5.3% during the forecast period from 2024 to 2032. Key Market Players: Ebastel, Nasacort, Omnaris, Grazax, Zyrtec, Xyzal, Astelin, Allegra, Ragwitek, Avamys, Claritin,...